Spero Therapeutics (SPRO) Price to FCF (2017 - 2026)
Spero Therapeutics' (SPRO) quarterly Price to FCF came in at 24.0 in Q2 2026, down 160.57% on a YoY basis from 39.62 in Q2 2025, and down 381.02% quarter-over-quarter from 8.54 in Q1 2026.
Powered by 
Analysis
Spero Therapeutics (SPRO) Price to FCF (2017 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has reported Price to FCF for 10 consecutive years, with 24.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Price to FCF fell 160.57% year-over-year to 24.0; the trailing twelve-month figure through Jun 2026 stood at 6.56 (up 230.23% YoY), and the FY2025 full-year result was 10.41, down 334.11% from the prior year.
- Price to FCF slipped to 24.0 in Q2 2026 per SPRO's latest filing, from 8.54 in the prior quarter.
- Across five years, Price to FCF topped out at 15.6 in Q1 2024 and bottomed at 89.56 in Q3 2022.
- Historically, Price to FCF has averaged 7.72 across 5 years, with a median of 3.93 in 2023.
- The sharpest annual moves came in 2024 and 2025: Price to FCF jumped 363.09% in 2024, then tumbled 555.04% in 2025.
- Over 5 years, Price to FCF stood at 1.46 in 2022, then sank by 404.68% to 4.45 in 2023, then surged by 46.05% to 2.4 in 2024, then sank by 555.04% to 15.74 in 2025, then sank by 52.46% to 24.0 in 2026.
- According to Business Quant data, Price to FCF over the past three periods registered 24.0, 8.54, and 15.74 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Spero Therapeutics | 67.82 Mn | 17.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.00 |
| Mar 31, 2026 | 8.54 |
| Dec 31, 2025 | -15.74 |
| Sep 30, 2025 | 6.08 |
| Jun 30, 2025 | -9.21 |
| Mar 31, 2025 | -10.06 |
| Dec 31, 2024 | -2.40 |
| Sep 30, 2024 | 5.70 |
| Jun 30, 2024 | -3.75 |
| Mar 31, 2024 | 15.60 |
| Dec 31, 2023 | -4.45 |
| Sep 30, 2023 | 4.03 |
| Jun 30, 2023 | -4.11 |
| Mar 31, 2023 | -5.93 |
| Dec 31, 2022 | 1.46 |
| Sep 30, 2022 | -89.56 |
| Jun 30, 2022 | -1.13 |
| Mar 31, 2022 | -10.10 |
| Dec 31, 2021 | -18.96 |
| Sep 30, 2021 | -119.79 |